Efficacy and safety of the noradrenaline reuptake inhibitor, TAS-303, in women with stress urinary incontinence: Results of a double-blind, randomized, placebo-controlled, early phase II trial.

Efficacy and safety of the noradrenaline reuptake inhibitor, TAS-303, in women with stress urinary incontinence: Results of a double-blind, randomized, placebo-controlled, early phase II trial. Takahashi S, Kato K, Takei M, Yokoyama O, Gotoh M. Int J Urol. 2021 Jan;28(1):82-90. doi: 10.1111/iju.14411. Epub 2020 Nov 3